Item# 1032-2: Recombinant tat HIV-1 MN
Concentration: See vial
Volume/vial: See vial
Diluent: 0.2 M KCl, 5mM Glutathione
Physical State: Frozen Liquid
Stability: At least 6 months at -75°C.
Application: ELISA, Western ELISA, Anti-tat Drug Screening, Immunization, Transcriptional Activation.
Description: Full length (101 amino acids) Recombinant HIV-1 MN tat produced in the E.coli Expression System.
Purification: This protein is purified by ion affinity and reverse phase HPLC to >95% purity, as determined by SDS-PAGE and HPLC.
Specificity: This protein binds to murine monoclonal antibodies of defined epitope specificity and rabbit and human serum polyclonal antibodies (HIV-1 converted serum) in ELISA and Western ELISA.
Biological Activity: The biological specificity of this protein was determined by LTR-Beta galactosidase induction in MAGI and MAGI-CCR5 cells. Tat in 1-10ug/ml range induced Beta-galactosidase activity 30-fold over un-treated cells.
Endotoxin: Less than 0.01 EU/mg of protein as determined by BioWhittaker Kinetic QCL Kit.
Application and Instructions for use
Recommended concentrations for use are approximate values. A dose dependent response assay should be performed to determine the optimal concentration for use in specific applications. Dilute tat stock solution in saline-phosphate buffer (150mM NaCl, 50mM sodiumphosphate, pH 6.5) immediately before use. Tat readily oxidizes in buffer solutions which may change its LTR- dependent transcriptional activation activity. Transcriptional activation assays with tat are performed in 1-10µg/ml range. ELISA and Western ELISA require tat in 10-100ng protein range.